Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kezar Life Sciences (KZR) Equity Average (2021 - 2025)

Kezar Life Sciences' Equity Average history spans 5 years, with the latest figure at $87.4 million for Q3 2025.

  • For Q3 2025, Equity Average fell 38.62% year-over-year to $87.4 million; the TTM value through Sep 2025 reached $87.4 million, down 38.62%, while the annual FY2024 figure was $152.2 million, 33.44% down from the prior year.
  • Equity Average for Q3 2025 was $87.4 million at Kezar Life Sciences, down from $97.4 million in the prior quarter.
  • Across five years, Equity Average topped out at $290.3 million in Q3 2022 and bottomed at $87.4 million in Q3 2025.
  • The 5-year median for Equity Average is $169.1 million (2024), against an average of $183.0 million.
  • The largest annual shift saw Equity Average skyrocketed 132.81% in 2022 before it plummeted 39.07% in 2025.
  • A 5-year view of Equity Average shows it stood at $158.2 million in 2021, then soared by 74.82% to $276.5 million in 2022, then dropped by 27.03% to $201.8 million in 2023, then crashed by 37.81% to $125.5 million in 2024, then crashed by 30.36% to $87.4 million in 2025.
  • Per Business Quant, the three most recent readings for KZR's Equity Average are $87.4 million (Q3 2025), $97.4 million (Q2 2025), and $110.0 million (Q1 2025).